AD, The most common inflammatory skin disorder worldwide, is a highly heterogeneous condition with current treatments that do ...

Data from a retrospective multicenter study, along with a review of previous trials, supported the real-world utility of ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Eczema is not contagious, and is a chronic disease that causes symptoms of dry, itchy skin that can appear like a red rash, with some patients reporting a burning sensation, tingling or stinging.

As temperatures drop, many people experience dry, red, and itchy skin, a condition that often worsens in winter.

Jonathan Wolleben, an analyst from JMP Securities, has initiated a new Buy rating on Astria Therapeutics (ATXS).Invest with Confidence: Follow ...

Self-reported manifestations of topical steroid withdrawal in atopic dermatitis include erythema, desquamation, dryness, and oozing.

Well, the scientists think that though the reaction may worsen the rash itself, it could also offer an immune response to ...

Varicella-zoster virus (VZV) is a known cause of meningoencephalitis, typically in immunocompromised inpatients. We report a ...

Ruxolitinib cream 1.5% was safe and effective for the treatment of children and adolescents with a 35% or greater body surface areas affected by atopic dermatitis, according to a study.Ruxolitinib ...

After a couple of days filled with investor nervousness, Arcutis Biotherapeutics has claimed FDA approval of Zoryve for the new indication of atopic dermatitis (AD), a common form of eczema.

Astria Therapeutics' focus on leveraging its half-life extension technology to create long-acting mAbs targeting derisked targets in established markets has positioned the company favorably in the ...